Search:

Search for text in:

separate each search
term with a space

Multiple terms:

Additional Search Filters:

Conference Years:

Days Within Meeting:

Conferences:

Availability:

Participation Type:

Topic Tracks*:

Organ Site Tracks*:

  • Sort by:
  • Browse by:
<< first | < prev page: of 14 records per page: next > | last >>
pages: 1 2 3 4 5 ... 11 12 13 14 presentations: 1 to 25 of 333
Engineering T cells for cancer: CARs in the clinic
Carl H. June
Abramson Cancer Ctr. of Univ. of Penn., Philadelphia, PA, United States
from AACR Annual Meeting 2014 on April 7, 2014 8:15 AM-10:15 AM
Investigating inhibition of the CD47 "don't eat me" signal to enable tumor phagocytic removal and augmented cross presentation to T cells
Irving L. Weissman
Stanford Univ. School of Medicine, Stanford, CA, United States
from AACR Annual Meeting 2014 on April 7, 2014 8:15 AM-10:15 AM
The curative potential of T cell transfer therapy for patients with cancer
Steven A. Rosenberg
National Cancer Inst., Bethesda, MD, United States
from AACR Annual Meeting 2014 on April 7, 2014 8:15 AM-10:15 AM
Immune modulation for cancer therapy: Assessing antagonists and agonists
Jedd D. Wolchok
Mem. Sloan-Kettering Cancer Ctr., New York, NY, United States
from AACR Annual Meeting 2014 on April 7, 2014 8:15 AM-10:15 AM
SU2C Scientific Advisory Committee Chairperson, Opening Remarks
Phillip A. Sharp
MIT Koch Inst. for Integrative Cancer Res., Cambridge, MA, United States
from AACR Annual Meeting 2014 on April 7, 2014 12:45 PM-2:15 PM
Bringing Epigenetic Therapy to the Forefront of Cancer Management
Stephen B. Baylin
Johns Hopkins Univ. School of Medicine, Baltimore, MD, United States
Julie R. Brahmer
Johns Hopkins Kimmel Comp. Cancer Ctr., Baltimore, MD, United States
from AACR Annual Meeting 2014 on April 7, 2014 12:45 PM-2:15 PM
Combining a PI3K Inhibitor and PARP Inhibitor in High Grade Serous Ovarian Cancer and Triple Negative Breast Cancers
Gordon B. Mills
UT MD Anderson Cancer Ctr., Houston, TX, United States
Ursula Matulonis
Dana-Farber Cancer Inst., Boston, MA, United States
from AACR Annual Meeting 2014 on April 7, 2014 12:45 PM-2:15 PM
Understanding Cancer Metastasis Through Circulating Tumor Cells
Mehmet Toner
Massachusetts General Hospital, Charlestown, MA, United States
Daniel A. Haber
Massachusetts General Hospital, Charlestown, MA, United States
from AACR Annual Meeting 2014 on April 7, 2014 12:45 PM-2:15 PM
An Integrated Approach to Targeting Breast Cancer Molecular Subtypes and Their 'Resistance' Phenotypes
Dennis J. Slamon
UCLA David Geffen School of Medicine, Los Angeles, CA, United States
Joan S. Brugge
Harvard Medical School, Boston, MA, United States
from AACR Annual Meeting 2014 on April 7, 2014 12:45 PM-2:15 PM
Cutting off the Fuel Supply: A New Approach to the Treatment of Pancreatic Cancer
Victor E. Velculescu
Johns Hopkins Kimmel Comp. Cancer Ctr., Baltimore, MD, United States
from AACR Annual Meeting 2014 on April 7, 2014 12:45 PM-2:15 PM
BET-bromodomain inhibitor OTX015 shows clinically meaningful activity at nontoxic doses: interim results of an ongoing phase I trial in hematologic malignancies
Esteban Cvitkovic
Oncoethix SA, Lausanne, Switzerland
from AACR Annual Meeting 2014 on April 7, 2014 1:00 PM-3:00 PM
Discussant
James E. Bradner
Dana-Farber Cancer Inst., Boston, MA, United States
from AACR Annual Meeting 2014 on April 7, 2014 1:00 PM-3:00 PM
Clinical activity of LY2835219, a novel cell cycle inhibitor selective for CDK4 and CDK6, in patients with metastatic breast cancer
Amita Patnaik
South Texas Accelerated Research Therapeutics (START), San Antonio, TX, United States
from AACR Annual Meeting 2014 on April 7, 2014 1:00 PM-3:00 PM
Discussant
Gary K. Schwartz
Columbia Univ. Irving Comp. Cancer Ctr., New York, NY, United States
from AACR Annual Meeting 2014 on April 7, 2014 1:00 PM-3:00 PM
A first-in-human phase I study of the safety and pharmacokinetic (PK) activity of DEDN6526A, an anti-endothelin B receptor (ETBR) antibody-drug conjugate (ADC), in patients with metastatic or unresectable melanoma
Jeffrey R Infante
Sarah Cannon Research Institute, Nashville, TN, United States
from AACR Annual Meeting 2014 on April 7, 2014 1:00 PM-3:00 PM
Discussant
Steven J. O'Day
Beverly Hills Cancer Center, Beverly Hills, CA, United States
from AACR Annual Meeting 2014 on April 7, 2014 1:00 PM-3:00 PM
Dabrafenib stimulates radioiodine uptake in BRAF V600E mutant advanced papillary thyroid cancer
Stephen M Rothenberg
Massachusetts General Hosp. Cancer Ctr., Boston, MA, United States
from AACR Annual Meeting 2014 on April 7, 2014 1:00 PM-3:00 PM
Discussant
Richard M. Marais
Cancer Research UK Manchester Institute, Manchester, United Kingdom
from AACR Annual Meeting 2014 on April 7, 2014 1:00 PM-3:00 PM
Invited Speaker
Lynda Chin
UT MD Anderson Cancer Ctr., Houston, TX, United States
from AACR Annual Meeting 2014 on April 7, 2014 7:00 AM-8:00 AM
Invited Speaker
Jill Mesirov
Broad Inst. of MIT and Harvard, Cambridge, MA, United States
from AACR Annual Meeting 2014 on April 7, 2014 7:00 AM-8:00 AM
Invited Speaker
Jiri Bartek
Danish Cancer Society - Inst. of Cancer Biology, Copenhagen, Denmark
from AACR Annual Meeting 2014 on April 7, 2014 7:00 AM-8:00 AM
Invited Speaker
Martin McMahon
UCSF Helen Diller Family Comp. Cancer Ctr., San Francisco, CA, United States
from AACR Annual Meeting 2014 on April 7, 2014 7:00 AM-8:00 AM
Invited Speaker
Stephen B. Gruber
USC/Norris Comprehensive Cancer Ctr., Los Angeles, CA, United States
from AACR Annual Meeting 2014 on April 7, 2014 7:00 AM-8:00 AM
Invited Speaker
Marcia R. Cruz-Correa
Univ. of Puerto Rico Comp. Cancer Ctr., San Juan, PR, United States
from AACR Annual Meeting 2014 on April 7, 2014 7:00 AM-8:00 AM
Introduction/Overview
Abby Sandler
National Cancer Institute, Bethesda, MD, United States
from AACR Annual Meeting 2014 on April 7, 2014 7:00 AM-8:00 AM
<< first | < prev page: of 14 records per page: next > | last >>
pages: 1 2 3 4 5 ... 11 12 13 14 presentations: 1 to 25 of 333